NovaBridge Biosciences (NBP) EBIT (2019 - 2025)
NovaBridge Biosciences (NBP) reported EBIT of -$72.9 million for Q4 2025, down 445.21% year-over-year from $21.1 million in Q4 2024, and down 710.99% on a QoQ basis from -$9.0 million in Q3 2025.
NovaBridge Biosciences (NBP) has 5 years of EBIT data on file, last reported at -$72.9 million in Q4 2025.
- Quarterly EBIT fell 445.21% year-over-year to -$72.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$94.3 million (down 83.31% YoY) and the FY2025 annual result came in at -$94.3 million, down 83.31% from the prior year.
- EBIT declined to -$72.9 million in Q4 2025 per NBP's latest filing, from -$9.0 million in the prior quarter.
- Across five years, EBIT topped out at -$5.3 million in Q1 2025 and bottomed at -$72.9 million in Q4 2025.
- The 3-year median for EBIT is -$12.0 million (2023), against an average of -$18.9 million.
- The widest annual swing landed in 2024, when EBIT surged 66.12%; it then plunged 445.21% in 2025.
- Tracing NBP's EBIT over 3 years: stood at -$39.5 million in 2023, then surged by 66.12% to -$13.4 million in 2024, then sank by 445.21% to -$72.9 million in 2025.
- Per Business Quant, the three latest NBP EBIT figures stand at -$72.9 million (Q4 2025), -$9.0 million (Q3 2025), and -$7.1 million (Q2 2025).
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -72.90 Mn |
| Sep 30, 2025 | -8.99 Mn |
| Jun 30, 2025 | -7.11 Mn |
| Mar 31, 2025 | -5.27 Mn |
| Dec 31, 2024 | -13.37 Mn |
| Sep 30, 2024 | -12.41 Mn |
| Jun 30, 2024 | -17.14 Mn |
| Mar 31, 2024 | -8.50 Mn |
| Dec 31, 2023 | -39.46 Mn |
| Sep 30, 2023 | -10.63 Mn |
| Jun 30, 2023 | -12.05 Mn |
| Dec 31, 2020 | -12.97 Mn |
| Sep 30, 2020 | 88.52 Bn |
| Dec 31, 2019 | -47.37 Mn |
| Sep 30, 2019 | -43.72 Mn |